Director of ID Pharmacy @IDConnect1 | U of Texas PharmD🤘🏼| Antifungal Nerd 🍄 | “Highly Enthusiastic”
Oct 23, 2020 • 35 tweets • 23 min read
Next up, the “What’s Hot in Antifungals?” session by the ever-insightful @DavidAndes, @IDPharmacist, and Dr. Sharon Chen. There’s a lot of development in the antifungal sphere so strap in! @MSG_ERC@GermHunterMD@FungalDoc@GRThompson@IDSA@SIDPharm 1/
So what are the current gaps in available antifungals? Notable gaps include parenteral only, PK distribution to sanctuary sites/urine, toxicity, DDIs, and MDR pathogens (I’m looking at you, the fungus formerly known as S. prolificans). 2/
Oct 22, 2020 • 15 tweets • 10 min read
Just finished watching the fantastic #IDWeek2020 session “Top Papers in Medical Mycology” by Drs. Jeniel Nett and @petergpappas, highly recommend watching. They covered notable papers, and I took a stab at high-level summaries with screenshots below. @MSG_ERC@IDSAInfo@SIDPharm1) 10.1371/journal.ppat.1007460 – NDV-3A Vaccine protects mice against MDR-C. auris infection; N-terminus of Als3 protein (major adhesion/invasin from C. alb) formulated with alum; Anti-Als3 Abs in mice recognized C. auris in vitro, blocked biofilm/enhanced macrophage killing.
Oct 22, 2020 • 4 tweets • 2 min read
Excellent points as always, Sam! Expanding, I think the concern is two-fold. Known known (SBECD nephrotoxicity), which as pointed out is low concern (review jasn.asnjournals.org/content/31/7/1… by @MAdamsick stating differences in SBECD exposure from animal studies and RDV course). 1/n
Known unknown – in renal dysfxn/failure, does accumulation of RDV/metabolites occur and lead to tox (including non-renal tox)? For RDV, primarily cleared by non-renal mechs (esterase hydrolysis), but main metabolite (GS-441524) reliant on renal clearance (49% in urine). 2/n
